We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMCOS
RNS Number : 3589X
Collagen Solutions PLC
28 August 2015
Collagen Solutions Plc
(the "Company" or the "Group")
Joins consortium developing new treatments for Parkinson's disease
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been chosen to participate in a new research project to develop novel treatments for Parkinson's disease.
The project is being led by CÚRAM, the Centre for Research in Medical Devices based at NUI Galway, who have secured EUR4 million in funding through the European Horizon 2020 grant programme. The project, entitled 'Development of Biomaterial-based Delivery Systems for Parkinson's disease - an Integrated Pan-European Approach', facilitates collaboration between world class researchers and industry partners to develop the first disease-modifying therapy for Parkinson's, which could slow down the progression of the disease rather than offering mere symptomatic benefits
As a key member of the consortium, Collagen Solutions will receive significant funding to develop various types of medical grade collagens for investigation over the duration of the project.
Dr Stewart White, CEO of Collagen Solutions plc commented: "Collagen Solutions is delighted to be part of such an esteemed consortium working on developing new therapies for such a devastating condition. I believe our shared success as part of the consortium provides further validation of the Company's reputation for developing and suppling consistent high quality medical grade collagen products for its international clients. Our R&D capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project."
Professor Abhay Pandit, Director of CÚRAM, stated that: "CÚRAMs strength lies in establishing unique networks of synergistic national and international collaborations, integrating world class clinical, academic and industrial partners. Collagen Solutions' ability to source, develop and manufacture collagen components for therapeutic use will be critical in meeting the requirements for a functional delivery formulation for the project. It is a mark of quality for all involved to have secured this grant funding, and we are very pleased to welcome Collagen Solutions to the consortium."
Enquiries:
Collagen Solutions Plc David Evans, Chairman Tel: 07881 484 785 Stewart White, CEO Tel: 0141 558 2008 Panmure Gordon & Co (Joint Tel: 0207 8862 714 Broker) Tel: 020 7886 2905 Robert Naylor (Corporate Finance) Maisie Atkinson (Corporate Broking) Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Mike Wort Mob: 07900 608 002
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUWCRUPAGAM
(END) Dow Jones Newswires
August 28, 2015 02:00 ET (06:00 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
